europeanpharmaceuticalreviewAugust 07, 2019
Tag: US , china , AI , Healthcare
In a new commentary article, titled ‘It Takes a Planet’, Eric Topol, MD, of Scripps Research and Kai-Fu Li, PhD, CEO of the China-based tech investment firm Sinovation Ventures have argued for more collaboration between China and the US on artificial intelligence (AI) development.
This comes in the wake of the US government ordering the AI company iCarbonX in China to divest its majority ownership stake in the Massachusetts-based company PatientsLikeMe.
"Chinese academics and companies already have unfettered access to personal health data," they write. "To compete in AI health, US companies will need access to clinical data on a similar scale. How will that be possible if the current isolationist policy continues?"
Topol and Li continue that big data has changed the landscape of medicine, with every individual representing vast amounts of medical information that no human can adequately process. This is occurring at a time when there are unacceptable levels of medical errors, inefficiency, waste, burnout and depression among clinicians, and high costs for medical care.
They also note that poor access to medical care among people living in rural areas increases inequities in healthcare.
"These problems mandate big thinking on how we can pool our resources to promote better health everywhere and for everyone," they continue. "We have at our fingertips technology capable of analysing petabytes of data. The difference now is that it is potentially achievable by capitalising on the ability to analyse the data rather than capitulating to the challenge.
"Let us embrace this opportunity by working together collaboratively across the planet for the greater good of all."
The commentary article was published in Nature Biotechnology.
-----------------------------------------------------------------------
Editor's Note:
If you have any suggestion to the content,
please email: Julia.Zhang@ubmsinoexpo.com
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: